NASH Drugs-EMEA Market Status and Trend Report 2013-2023
Report Summary
NASH Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on NASH Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of NASH Drugs 2013-2017, and development forecast 2018-2023
Main market players of NASH Drugs in EMEA, with company and product introduction, position in the NASH Drugs market
Market status and development trend of NASH Drugs by types and applications
Cost and profit status of NASH Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA NASH Drugs market as:
EMEA NASH Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA NASH Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
PPAR Agonist
FXR Agonist
Caspase Inhibitor
PDE Inhibitor
Other
EMEA NASH Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
NASH
EMEA NASH Drugs Market: Players Segment Analysis (Company and Product introduction, NASH Drugs Sales Volume, Revenue, Price and Gross Margin):
Galmed
Intercept
Tobira
Genfit
Conatus
Galectin
Gilead
NuSirt
MediciNova
Shire
Novo Nordisk
Raptor Pharmaceuticals
Zydus Cadila
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
NASH Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on NASH Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of NASH Drugs 2013-2017, and development forecast 2018-2023
Main market players of NASH Drugs in EMEA, with company and product introduction, position in the NASH Drugs market
Market status and development trend of NASH Drugs by types and applications
Cost and profit status of NASH Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA NASH Drugs market as:
EMEA NASH Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA NASH Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
PPAR Agonist
FXR Agonist
Caspase Inhibitor
PDE Inhibitor
Other
EMEA NASH Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
NASH
EMEA NASH Drugs Market: Players Segment Analysis (Company and Product introduction, NASH Drugs Sales Volume, Revenue, Price and Gross Margin):
Galmed
Intercept
Tobira
Genfit
Conatus
Galectin
Gilead
NuSirt
MediciNova
Shire
Novo Nordisk
Raptor Pharmaceuticals
Zydus Cadila
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF NASH DRUGS
1.1 Definition of NASH Drugs in This Report
1.2 Commercial Types of NASH Drugs
1.2.1 PPAR Agonist
1.2.2 FXR Agonist
1.2.3 Caspase Inhibitor
1.2.4 PDE Inhibitor
1.2.5 Other
1.3 Downstream Application of NASH Drugs
1.3.1 NASH
1.4 Development History of NASH Drugs
1.5 Market Status and Trend of NASH Drugs 2013-2023
1.5.1 EMEA NASH Drugs Market Status and Trend 2013-2023
1.5.2 Regional NASH Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of NASH Drugs in EMEA 2013-2017
2.2 Consumption Market of NASH Drugs in EMEA by Regions
2.2.1 Consumption Volume of NASH Drugs in EMEA by Regions
2.2.2 Revenue of NASH Drugs in EMEA by Regions
2.3 Market Analysis of NASH Drugs in EMEA by Regions
2.3.1 Market Analysis of NASH Drugs in Europe 2013-2017
2.3.2 Market Analysis of NASH Drugs in Middle East 2013-2017
2.3.3 Market Analysis of NASH Drugs in Africa 2013-2017
2.4 Market Development Forecast of NASH Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of NASH Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of NASH Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of NASH Drugs in EMEA by Types
3.1.2 Revenue of NASH Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of NASH Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of NASH Drugs in EMEA by Downstream Industry
4.2 Demand Volume of NASH Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of NASH Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of NASH Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of NASH Drugs by Downstream Industry in Africa
4.3 Market Forecast of NASH Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NASH DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 NASH Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 NASH DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of NASH Drugs in EMEA by Major Players
6.2 Revenue of NASH Drugs in EMEA by Major Players
6.3 Basic Information of NASH Drugs by Major Players
6.3.1 Headquarters Location and Established Time of NASH Drugs Major Players
6.3.2 Employees and Revenue Level of NASH Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NASH DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Galmed
7.1.1 Company profile
7.1.2 Representative NASH Drugs Product
7.1.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galmed
7.2 Intercept
7.2.1 Company profile
7.2.2 Representative NASH Drugs Product
7.2.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Intercept
7.3 Tobira
7.3.1 Company profile
7.3.2 Representative NASH Drugs Product
7.3.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Tobira
7.4 Genfit
7.4.1 Company profile
7.4.2 Representative NASH Drugs Product
7.4.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Genfit
7.5 Conatus
7.5.1 Company profile
7.5.2 Representative NASH Drugs Product
7.5.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Conatus
7.6 Galectin
7.6.1 Company profile
7.6.2 Representative NASH Drugs Product
7.6.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galectin
7.7 Gilead
7.7.1 Company profile
7.7.2 Representative NASH Drugs Product
7.7.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Gilead
7.8 NuSirt
7.8.1 Company profile
7.8.2 Representative NASH Drugs Product
7.8.3 NASH Drugs Sales, Revenue, Price and Gross Margin of NuSirt
7.9 MediciNova
7.9.1 Company profile
7.9.2 Representative NASH Drugs Product
7.9.3 NASH Drugs Sales, Revenue, Price and Gross Margin of MediciNova
7.10 Shire
7.10.1 Company profile
7.10.2 Representative NASH Drugs Product
7.10.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Shire
7.11 Novo Nordisk
7.11.1 Company profile
7.11.2 Representative NASH Drugs Product
7.11.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.12 Raptor Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative NASH Drugs Product
7.12.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Raptor Pharmaceuticals
7.13 Zydus Cadila
7.13.1 Company profile
7.13.2 Representative NASH Drugs Product
7.13.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Zydus Cadila
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NASH DRUGS
8.1 Industry Chain of NASH Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NASH DRUGS
9.1 Cost Structure Analysis of NASH Drugs
9.2 Raw Materials Cost Analysis of NASH Drugs
9.3 Labor Cost Analysis of NASH Drugs
9.4 Manufacturing Expenses Analysis of NASH Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF NASH DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of NASH Drugs in This Report
1.2 Commercial Types of NASH Drugs
1.2.1 PPAR Agonist
1.2.2 FXR Agonist
1.2.3 Caspase Inhibitor
1.2.4 PDE Inhibitor
1.2.5 Other
1.3 Downstream Application of NASH Drugs
1.3.1 NASH
1.4 Development History of NASH Drugs
1.5 Market Status and Trend of NASH Drugs 2013-2023
1.5.1 EMEA NASH Drugs Market Status and Trend 2013-2023
1.5.2 Regional NASH Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of NASH Drugs in EMEA 2013-2017
2.2 Consumption Market of NASH Drugs in EMEA by Regions
2.2.1 Consumption Volume of NASH Drugs in EMEA by Regions
2.2.2 Revenue of NASH Drugs in EMEA by Regions
2.3 Market Analysis of NASH Drugs in EMEA by Regions
2.3.1 Market Analysis of NASH Drugs in Europe 2013-2017
2.3.2 Market Analysis of NASH Drugs in Middle East 2013-2017
2.3.3 Market Analysis of NASH Drugs in Africa 2013-2017
2.4 Market Development Forecast of NASH Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of NASH Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of NASH Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of NASH Drugs in EMEA by Types
3.1.2 Revenue of NASH Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of NASH Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of NASH Drugs in EMEA by Downstream Industry
4.2 Demand Volume of NASH Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of NASH Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of NASH Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of NASH Drugs by Downstream Industry in Africa
4.3 Market Forecast of NASH Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NASH DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 NASH Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 NASH DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of NASH Drugs in EMEA by Major Players
6.2 Revenue of NASH Drugs in EMEA by Major Players
6.3 Basic Information of NASH Drugs by Major Players
6.3.1 Headquarters Location and Established Time of NASH Drugs Major Players
6.3.2 Employees and Revenue Level of NASH Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NASH DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Galmed
7.1.1 Company profile
7.1.2 Representative NASH Drugs Product
7.1.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galmed
7.2 Intercept
7.2.1 Company profile
7.2.2 Representative NASH Drugs Product
7.2.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Intercept
7.3 Tobira
7.3.1 Company profile
7.3.2 Representative NASH Drugs Product
7.3.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Tobira
7.4 Genfit
7.4.1 Company profile
7.4.2 Representative NASH Drugs Product
7.4.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Genfit
7.5 Conatus
7.5.1 Company profile
7.5.2 Representative NASH Drugs Product
7.5.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Conatus
7.6 Galectin
7.6.1 Company profile
7.6.2 Representative NASH Drugs Product
7.6.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galectin
7.7 Gilead
7.7.1 Company profile
7.7.2 Representative NASH Drugs Product
7.7.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Gilead
7.8 NuSirt
7.8.1 Company profile
7.8.2 Representative NASH Drugs Product
7.8.3 NASH Drugs Sales, Revenue, Price and Gross Margin of NuSirt
7.9 MediciNova
7.9.1 Company profile
7.9.2 Representative NASH Drugs Product
7.9.3 NASH Drugs Sales, Revenue, Price and Gross Margin of MediciNova
7.10 Shire
7.10.1 Company profile
7.10.2 Representative NASH Drugs Product
7.10.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Shire
7.11 Novo Nordisk
7.11.1 Company profile
7.11.2 Representative NASH Drugs Product
7.11.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.12 Raptor Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative NASH Drugs Product
7.12.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Raptor Pharmaceuticals
7.13 Zydus Cadila
7.13.1 Company profile
7.13.2 Representative NASH Drugs Product
7.13.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Zydus Cadila
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NASH DRUGS
8.1 Industry Chain of NASH Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NASH DRUGS
9.1 Cost Structure Analysis of NASH Drugs
9.2 Raw Materials Cost Analysis of NASH Drugs
9.3 Labor Cost Analysis of NASH Drugs
9.4 Manufacturing Expenses Analysis of NASH Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF NASH DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
